Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study.

about

Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study.

Item

http://www.wikidata.org/entity/Q40303819

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Relapsed chronic lymphocytic l ...... im results of the PERLE study.

@en

type

Item

label

Relapsed chronic lymphocytic l ...... im results of the PERLE study.

@en

prefLabel

Relapsed chronic lymphocytic l ...... im results of the PERLE study.

@en

P1476

Relapsed chronic lymphocytic l ...... im results of the PERLE study.

@en

P2093

Adrian Tempescul

http://www.w3.org/2001/XMLSchema#string

Alain Delmer

http://www.w3.org/2001/XMLSchema#string

Aurélie Bardet

http://www.w3.org/2001/XMLSchema#string

Brigitte Dreyfus

http://www.w3.org/2001/XMLSchema#string

Béatrice Mahé

http://www.w3.org/2001/XMLSchema#string

Driss Chaoui

http://www.w3.org/2001/XMLSchema#string

Eric Jourdan

http://www.w3.org/2001/XMLSchema#string

Hubert Orfeuvre

http://www.w3.org/2001/XMLSchema#string

Laurence Sanhes

http://www.w3.org/2001/XMLSchema#string

Marc Maynadié

http://www.w3.org/2001/XMLSchema#string

P2860

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany-data from the Prospective Tumour Registry Lymphatic Neoplasms.

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study.

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.

Treatment practice in the elderly patient with chronic lymphocytic leukemia-analysis of the combined SEER and Medicare database.

Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)

Chronic lymphocytic leukemia: planning for an aging population

P304

1366-1375

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428194.2016.1243673

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28271952

http://www.w3.org/2001/XMLSchema#string

P921

lymphocyte